Seres cuts its workforce by nearly half, focuses on FDA-approved drug

Seres Therapeutics Inc. is making big cuts to its workforce as it prioritizes the commercial launch of a treatment that received approval from the U.S. Food and Drug Administration earlier this year.

Previous Red Sox Hall of Famer Pedro Martinez buys home soon after selling one (Photos)
Next Local breakfast food manufacturer betting big on regenerative supply chains